Generation and characterization of a monoclonal IgG antibody to polyethylene glycol

Hybridoma

Volumn 26, Issue 3, 2007, Pages 168-172

  Wunderlich, David A ^a   MacDougall, Margit ^a   Mierz, Diane V ^a   Toth, Joshuaine G ^a   Buckholz, Thomas M ^a   Lumb, Kevin J ^a   Vasavada, Haren ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10F05; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DERIVATIZATION; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN PURIFICATION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMOCYANIN; HYBRIDOMAS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PEPTIDES; POLYETHYLENE GLYCOLS;

EID: 34447313393     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2007.006     Document Type: Article

References (11)

1. Harris JM and Chess RB: Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214-221.
2. Greenwald RB, Choe YH, McGuire J, and Conover CD: Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 2003;55:217-250.
3. Riehter AW and Akerblom E: Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol 1983;70:124-131.
4. Srroda K, Rydlewski J, Langner M, Kozubek A, Grzybek M, and Sikorski AF: Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell Mol Biol Lett 2005;10:37-47.
5. Cheng TL, Wu PY, Wu MF, Chern JW, and Roffler SR: Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjug Chem 1999;10:520-528.
6. Cheng TL, Cheng CM, Chen BM, Tsao DA, Chuang KH, Hsiao SW, Lin YH, and Roffler SR: Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles. Bioconjug Chem 2005;16:1225-1231.
7. Bartal AH and Hirshaut Y: Methods of Hybridoma Formation. Humana Press, Clifton, NJ, 1987.
8. Pan CQ, Buxton JM, Yung SL, Tom I, Yang L, Chen H, MacDougall M, Bell A, Claus TH, Clairmont KB, and Whelan JP: Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J Biol Chem 2006;281:12506-12515.
9. Clairmont KB, Buckholz TM, Pellegrino CM, Buxton JM, Barucci N, Bell A, Ha S, Li F, Claus TH, Salhanick AI, and Lumb KJ: Engineering of a VPAC2 receptor peptide agonist to impart dipeptidyl peptidase IV stability and enhance in vivo glucose disposal. J Med Chem 2006;49:7545-7548.
10. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, and Hershfield MS: Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006;8:R12.
11. Judge A, McClintock K, Phelps JR, and Maclachlan I: Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 2006;13:328-337.